Pharmacological options for advanced cancer patients with loss of appetite and weight

Bibliography

• DEWYS WB, BEGG C, LAVIN PT et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. (1980) 69(4):491-497.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, LAURIE JA, WIEAND HS et al.: Prospective evaluation of prognostic variables from patient- completed questionnaires. J. Clin. Oncol. (1994) 12(3):601-607.
   PubMed Web of Science ®Google Scholar
• MURAD AM, SKARE NG, VINHOLES J et al.: Phase II multicenter trial of docetaxel, epirubicin and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe and active regimen. Gastric Cancer (2006) 9:99-105.
   PubMedGoogle Scholar
• STEYN RS, GRENIER I, DARNTON SJ et al.: Weight gain as an indicator of response to chemotherepy for oesophageal carcinoma. Clin. Oncol. (1995) 7:382-384.
   PubMedGoogle Scholar
• MOERTEL C, SCHUTT AJ, REITEMEIER, RJ, HAHN RG: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer (1974) 33:1607.
   PubMed Web of Science ®Google Scholar
• BRUERA ER, ROCA E, CEDARO L, CARRARO S, CHACON R: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat. Rep. (1985) 69(7-8):751-754.
   PubMedGoogle Scholar
• POPIELA TL, LUCCHI R, GIONGO F: Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur. J. Cancer Clin. Oncol. (1989) 25(12):1823-1829.
   PubMedGoogle Scholar
• LOPRINZI CL, ELLISON NM, SCHAID DJ et al.: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer Inst. (1990) 82(13):1127-1132.
   PubMed Web of Science ®Google Scholar
• BERENSTEIN EG, ORTIZ Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2005) 2:CD004310.
   Google Scholar
• LOPRINZI CL, MICHALAK JC, SCHAID DJ et al.: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J. Clin. Oncol. (1993) 11(4):762-767.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, KUGLER JW, SLOAN JA et al.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J. Clin. Oncol. (1999) 17(10):3299-3306.
   PubMed Web of Science ®Google Scholar
• KARDINAL CG, LOPRINZI CL, SCHAID DJ et al.: A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer (1990) 65(12):2657-2662.
   PubMed Web of Science ®Google Scholar
• MOERTEL CK, RUBIN J: A study of cyproheptadine in the treatment of metastatic carcinoid tumour and the malignant carcinoid syndrome. Cancer (1991) 1(67):33-36.
   Web of Science ®Google Scholar
• NELSON K, WALSH D, DEETER P, SHEEHAN F: A Phase II study of δ-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliat. Care (1994) 10(1):14-18.
   PubMedGoogle Scholar
• JATOI A, WINDSCHITL HE, LOPRINZI CL et al.: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. (2002) 20(2):567-573.
   PubMed Web of Science ®Google Scholar
• STRASSER F, LUFTNER D, POSSINGER K et al.: Comparison of orally administered cannabis extract and δ-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, Phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis In Cachexia Study Group. J. Clin. Oncol. (2006) 24(21):3394-3400.
   PubMed Web of Science ®Google Scholar
• PRICE S, TISDALE MJ: Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res. (1998) 58(21):4827-4831.
   PubMed Web of Science ®Google Scholar
• WIGMORE S, FEARON KC, MAINGAY JP, ROSSA JA: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of IL-6. Clin. Sci. (1997) 92(2):215-221.
   PubMed Web of Science ®Google Scholar
• BARBER M, ROSS JA, VOSS AC et al.: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br. J. Cancer (1999) 81(1):80-86.
   PubMed Web of Science ®Google Scholar
• BRUERA E, STRASSER F, PALMER JL et al.: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J. Clin. Oncol. (2003) 1(21):129-134.
   Google Scholar
• JATOI A, ROWLAND K, LOPRINZI CL et al.: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J. Clin. Oncol. (2004) 15(22):2469-2476.
   Google Scholar
• FEARON KC, VON MEYENFELDT MF, MOSES AG et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut (2003) 52(10):1479-1486.
   PubMed Web of Science ®Google Scholar
• FEARON KC, BARBER MD, MOSES AG et al.: Double-blind, placebo-controlled, randomized study of eicospentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol. (2006) 24(21):3401-3407.
   PubMed Web of Science ®Google Scholar
• GUNEY Y, OZEL TURKCU U, HICSONMEZ A et al.: Ghrelin may reduce radiation-induced mucositis and anorexia in head and neck cancer. Medical Hypotheses (2007) 68:538-540.
   PubMed Web of Science ®Google Scholar
• CARNAC G, RICAUD S, VERNUS B, BONNIEU A: Myostatin: biology and clinical relevance. Mini Rev. Med. Chem. (2006) 6:765-770.
   PubMed Web of Science ®Google Scholar
• LISSONI P, PAOLOROSSI F, TANCINI G et al.: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer (1996) 32A(8):1340-1343.
   PubMed Web of Science ®Google Scholar
• LISSONI P, PAOLOROSSI F, ARDIZZOIA A et al.: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal. Res. (1997) 23(1):1.
   PubMed Web of Science ®Google Scholar
• GORDON J, TREBBLE TM, ELLIS RD et al.: Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 54(4):540-545.
   PubMed Web of Science ®Google Scholar
• KHAN Z, SIMPSON EJ, COLE AT et al.: Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment. Pharmacol. Ther. (2003) 1(17):677-682.
   Google Scholar
• VON ROENN JH, TCHEKMEDYIAN S, HOFFMAN RM et al.: Safety of oxandrolone in cancer-related weight loss. Proc. Am. Soc. Clin. Oncol. (2003) 22: Abstract 3013.
   Google Scholar